15th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy, May 19- 21, 2014, Washington, DC

Conference Reports for NATAP


16th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy May 26-28, 2015 Washington, DC

	The 16th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy - written by Courtney V. Fletcher, Pharm.D. Dean and Professor College of Pharmacy University of Nebraska Medical Center Jennifer J. Kiser, Pharm.D. Assistant Professor School of Pharmacy University of Colorado at Denver - (06/17/15) Lack of Effect of Oral Cabotegravir on the Pharmacokinetics of a Levonorgestrel/Ethinyl Estradiol Containing Oral Contraceptive in Healthy Adult Females - (06/12/15) Nanoformulations: Update from ViiV Healthcare - (06/12/15) No Pharmacokinetic Interaction Between HCV Inhibitors Grazoprevir/Elbasvir with Rilpivirine - (06/08/15) Coadministration of HCV Protease Inhibitor Grazoprevir With HCV NS5A Inhibitor Elbasvir Has No Effect On Pravastatin But Increases Rosuvastatin Exposure In Healthy Subjects - (06/08/15) Drug-Drug Interactions of Ombitasvir/Paritaprevir/r plus Dasabuvir with Dolutegravir or Abacavir plus Lamivudine - (06/08/15) Drug-Drug Interactions of Commonly Used Medications with Direct Acting Antiviral HCV Combination Therapy of Paritaprevir/r, Ombitasvir and Dasabuvir - (06/08/15) Effect of Comedications on Paritaprevir, Ritonavir, Ombitasvir, Dasabuvir and Ribavirin Pharmacokinetics - (06/08/15) Pharmacokinetics of Dasabuvir when Administered with Ombitasvir, Paritaprevir and Ritonavir in Healthy Volunteers - (06/08/15) Drug Interactions with Direct Acting Antiviral Combination of Paritaprevir/Ritonavir + Ombitasvir - (06/08/15) Doravirine [Merck New NNRTI MK-1439] Efficacy Exposure-Response Analysis at Week 48 and Implications1 and Doravirine Pharmacokinetics After Switching from Efavirenz Therapy in Healthy Volunteers2 - (06/08/15) A 2-Way Steady State Pharmacokinetic Interaction Study of Doravirine (MK-1439) and Dolutegravir - (06/08/15) An Evaluation of Doravirine Pharmacokinetics When Switching From Efavirenz to Doravirine Treatment [poster] - (06/08/15) Doravirine Efficacy Exposure-Response Analysis at Week 48 and Implications [poster] - (06/08/15) Administration of a Supratherapeutic Dose of Doravirine Does not Result in a Clinically Meaningful Increase in QTc - (06/08/15) Moderate Hepatic Impairment Does not Affect Doravirine Pharmacokinetics - (06/08/15) Effect of Ketoconazole on the Pharmacokinetics of Doravirine (MK-1439), a Novel Non-Nucleoside Reverse Transcriptase Inhibitor for the Treatment of HIV-1 Infection - (06/08/15) Effect of Doravirine (MK-1439) on the Pharmacokinetics of an Oral Contraceptive (Ethinyl Estradiol and Levonorgestrel) - (06/08/15) Drug Interactions Between the Anti-HCV Regimen Ledipasvir/Sofosbuvir and Antiretrovirals - (06/03/15) Drug Interactions Between Anti-HCV Antivirals Ledipasvir/Sofosbuvir and Integrase Strand Transfer Inhibitor-Based Regimens......"LDV/SOF may be coadministered with E/C/F/TAF without monitoring" - (06/03/15) Drug-Drug Interactions with Grazoprevir/Elbasvir: Practical Considerations for the Care of HIV/HCV Co-Infected Patients - (06/03/15) Assessment of Drug-Drug Interactions Between Daclatasvir and Darunavir/Ritonavir or Lopinavir/Ritonavir - (06/03/15) HIV-1 Attachment Inhibitor Prodrug BMS-663068: Assessment of Interactions with Raltegravir in Treatment-Experienced HIV-1-Infected Subjects & Efficacy/Safety - (06/02/15) Safety, Efficacy, and Pharmacokinetics of the Integrase Inhibitor-Based E/C/F/TAF Single-Tablet Regimen in Treatment-Naïve HIV-Infected Adolescents Through 24 Weeks of Treatment - (06/02/15) Pharmacokinetics (PK) of Etravirine (ETR) in HIV-1-Infected Pregnant Women - (06/02/15) Rilpivirine population pharmacokinetic modeling in antiretroviral-naïve, HIV-1-infected adolescents in PAINT - (06/02/15) Standard Daclatasvir Dose OK With Darunavir/RTV or Lopinavir/RTV - written by Mark Mascolini - (06/01/15) Possible Dose Adjustments With Four Drugs and Abbvie 3D HCV Regimen - written by Mark Mascolini - (06/01/15) Triple-DAA Combo Cuts SSRI Levels by One Third, But No Dose Adjustment Needed - written by Mark Mascolini - (06/01/15) Almost Three Quarters of HIV/HCV Group May Have DAA-ARV Interactions - written by Mark Mascolini - (06/01/15) DAAs Grazoprevir and Elbasvir Boost Levels of Rosuvastatin But Not Pravastatin - written by Mark Mascolini - (06/01/15) Assessment of Drug-Drug Interactions Between Daclatasvir and Darunavir/Ritonavir or Lopinavir/Ritonavir - (06/01/15) Readying HIV/HCV Coinfected Patients for HCV Treatment: Occurrence and Management of Antiviral Interactions....[can patients switch their HIV regimen?] - (06/01/15) Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir: Drug Interactions with Antiretroviral Agents - (06/01/15) Therapeutic drug monitoring of daclatasvir in HIV/HCV co-infected patients receiving darunavir/ritonavir 800/100mg once-daily - (06/01/15) Prediction of Intracellular (IC) Tenofovir Diphosphate (TFV-DP) and Emtricitabine Triphosphate (FTC-TP) Concentrations Following Drug Intake Cessation - (06/01/15) Pharmacokinetics (PK) of once-daily dolutegravir (DTG) and elvitegravir/cobicistat (EVG/COBI) following drug cessation - (06/01/15) MICROBOOSTING OF ATAZANAVIR 300 MG WITH 50 MG VERSUS 100MG OF RITONAVIR DAILY IN HIV-INFECTED PATIENTS - (06/01/15) Population Viral Kinetic Modeling: SVR Prediction in HCV GT-3 Cirrhotic Patients With 24 Weeks of Daclatasvir + Sofosbuvir Administration - (05/29/15) Evaluation of Drug Interactions between Dolutegravir and Daclatasvir in Healthy Subjects - (05/29/15) Pharmacokinetic-Pharmacodynamic Modeling and Simulation of the Virologic Response of Dolutegravir in HIV-Infected Patients with Integrase Inhibitor Resistant Virus - (05/29/15) Doravirine Efficacy Exposure-Response Analysis at Week 48 and Implications1 and Doravirine Pharmacokinetics After Switching from Efavirenz Therapy in Healthy Volunteers2 - (05/29/15) Evaluation of PK/PD Relationships Between Ribavirin and Sustained Virologic Response in HCV-Genotype 3 Infected Subjects in the Sofosbuvir Phase 3 Program - (05/29/15) Doubling Dolutegravir Dose Has Little Impact on Controlling Resistant HIV - written by Mark Mascolini - (05/29/15) Antabuse (Disulfiram) Has Linear Exposure-Response Profile in Activating Latent HIV - written by Mark Mascolini - (05/29/15) Dolutegravir Persists Longer Than Elvitegravir After Dosing Stops - written by Mark Mascolini - (05/29/15) Good Response to TAF Plus EVG/COBI/FTC in Adolescents Through 24 Weeks - written by Mark Mascolini - (05/29/15) Low Darunavir Troughs at 800 Mg Once Daily With Stribild - written by Mark Mascolini - (05/29/15) Tenofovir Lower in Plasma, Higher in PBMCs, With TAF Versus TDF - written by Mark Mascolini - (05/29/15) Merck Sees No Dose-Response Relationship With Doravirine, a New Nonnucleoside - written by Mark Mascolini - (05/29/15) Model Predicts Higher SVR With 24- vs 12-Week Daclatasvir/Sofosbuvir for HCV-3 Cirrhotics - written by Mark Mascolini - (05/29/15)